Oric Pharmaceuticals Inc (ORIC)
NASDAQ:ORIC
Want to see ORIC full AI Analyst Report?
Top Page
Oric Pharmaceuticals
(NASDAQ:ORIC)
Select Model
Select Model
Rating:46Neutral
Price Target:
$8.00
▼(-25.58% Downside)
Action:Reiterated
Date:05/09/26
The score is primarily held down by weak financial performance (no revenue, large and widening losses, and sustained negative free cash flow) and bearish technicals (price below major moving averages with negative MACD). A stronger balance sheet with minimal debt and a positive Phase 3 advancement announcement provide partial support, but they do not offset the ongoing cash-burn and downtrend signals.
Positive Factors
Balance sheet strength
ORIC's low leverage and sizable equity base reduce financial distress risk and provide management flexibility to fund multi-year oncology R&D without immediate reliance on debt. This structural balance-sheet strength supports continued investment in registrational trials, helping sustain program development even amid operating losses.
Negative Factors
Pre-revenue with widening losses
As a pre-revenue biotech, ORIC lacks recurring product sales and posted materially larger losses year-over-year. Persistently widening deficits reflect rising R&D spend and limited operating leverage, meaning the firm cannot internally finance growth. This structural absence of revenue increases dependency on external funding to reach commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
ORIC's low leverage and sizable equity base reduce financial distress risk and provide management flexibility to fund multi-year oncology R&D without immediate reliance on debt. This structural balance-sheet strength supports continued investment in registrational trials, helping sustain program development even amid operating losses.
Read all positive factors
Oric Pharmaceuticals (ORIC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$870.58M
Dividend YieldN/A
Average Volume (3M)1.47M
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue GrowthN/A
EPS Growth23.91%
CountryUS
Employees122
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.44
Shares Outstanding103,517,560
10 Day Avg. Volume1,500,481
30 Day Avg. Volume1,466,391
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-6.30
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.56K
Enterprise Value/Ebitda-5.83
Forecast
1Y Price Target
$20.89Price Target Upside94.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.45
Revenue Forecast (FY)N/A
Oric Pharmaceuticals Business Overview & Revenue Model
Company Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule i...
How the Company Makes Money
ORIC does not have publicly disclosed recurring revenue from marketed products; as a clinical-stage company, it primarily finances operations through capital raising activities rather than product revenue. Its cash inflows have historically been g...
Oric Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
63
Positive
Cash Flow
25
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -320.00K | -1.22M | -1.11M | -1.03M | 0.00 | 0.00 |
| EBITDA | -140.59M | -128.25M | -126.74M | -109.75M | -85.80M | -77.97M |
| Net Income | -135.21M | -129.47M | -127.85M | -100.70M | -89.12M | -78.72M |
Balance Sheet | ||||||
| Total Assets | 436.76M | 411.00M | 274.14M | 254.69M | 250.36M | 298.64M |
| Cash, Cash Equivalents and Short-Term Investments | 281.93M | 281.49M | 255.96M | 208.19M | 206.27M | 236.98M |
| Total Debt | 0.00 | 11.55M | 3.18M | 10.21M | 12.10M | 1.93M |
| Total Liabilities | 21.20M | 26.64M | 31.02M | 30.60M | 28.01M | 25.67M |
| Stockholders Equity | 415.56M | 384.36M | 243.12M | 224.09M | 222.35M | 272.98M |
Cash Flow | ||||||
| Free Cash Flow | -111.36M | -114.08M | -113.85M | -86.54M | -77.22M | -60.48M |
| Operating Cash Flow | -110.88M | -113.37M | -112.66M | -85.69M | -75.14M | -59.54M |
| Investing Cash Flow | -188.46M | -148.03M | 22.14M | -43.40M | -109.25M | 158.44M |
| Financing Cash Flow | 306.39M | 245.26M | 126.55M | 85.66M | 25.23M | 49.13M |
Oric Pharmaceuticals Technical Analysis
Negative
10.75
Price Trends
10.16
Negative
10.56
Negative
10.86
Negative
Market Momentum
-0.61
Positive
38.03
Neutral
24.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORIC, the sentiment is Negative. The current price of 10.75 is above the 20-day moving average (MA) of 9.15, above the 50-day MA of 10.16, and below the 200-day MA of 10.86, indicating a bearish trend. The MACD of -0.61 indicates Positive momentum. The RSI at 38.03 is Neutral, neither overbought nor oversold. The STOCH value of 24.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ORIC.
Oric Pharmaceuticals Risk Analysis
Oric Pharmaceuticals disclosed 98 risk factors in its most recent earnings report. Oric Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oric Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $6.25B | -63.24 | -31.25% | ― | ― | 22.31% | |
67 Neutral | $1.97B | -32.92 | -24.53% | ― | ― | 27.89% | |
64 Neutral | $9.36B | -25.13 | -43.02% | ― | -100.00% | -24.90% | |
56 Neutral | $911.54M | -55.77 | 4.75% | ― | 15.66% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $870.58M | -9.34 | -35.33% | ― | ― | 23.91% | |
42 Neutral | $511.15M | -3.14 | -188.82% | ― | 4.89% | 24.20% |
* Healthcare Sector Average
ORIC
Oric Pharmaceuticals
8.41
2.46
41.34%
SYRE
Spyre Therapeutics
71.92
56.85
377.24%
TRVI
Trevi Therapeutics
13.88
7.85
130.18%
PRAX
Praxis Precision Medicines
335.61
297.30
776.04%
PHAR
Pharming Group
12.87
2.37
22.57%
PRME
Prime Medicine, Inc.
2.83
1.60
130.08%
Oric Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related Announcements
Oric Advances Rinzimetostat Toward First Prostate Cancer Phase 3
Positive
Apr 1, 2026
On March 31, 2026, ORIC Pharmaceuticals presented an update on dose optimization data from its Phase 1b trial of rinzimetostat (ORIC-944) in prostate cancer. The company has selected a 400 mg once-daily dose of rinzimetostat in combination with da...
Private Placements and FinancingRegulatory Filings and Compliance
Oric Pharmaceuticals Launches New 2026 ATM Share Program
Neutral
Feb 23, 2026
On May 6, 2021, ORIC Pharmaceuticals, Inc. entered into an Open Market Sale Agreement with Jefferies LLC to sell common shares through an at-the-market offering program, using Jefferies as sales agent under an effective shelf registration filed on...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.